Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Amatruda

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
International Journal of Obesity (2005)|March 10, 2010
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose studyJ Proietto, A Rissanen, J B Harp, et al.
Obesity (Silver Spring, Md.)|April 12, 2007
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight lossNgozi Erondu, Thomas Wadden, Ira Gantz, et al.
Diabetes, Obesity & Metabolism|June 4, 2008
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyJ C N Chan, R Scott, J C Arjona Ferreira, et al.
Current Medical Research and Opinion|March 25, 2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialNir Barzilai, Hua Guo, Erin M Mahoney, et al.
International Journal of Clinical Practice|January 18, 2011
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetesK H Yoon, G R Shockey, R Teng, et al.
Diabetes, Obesity & Metabolism|January 23, 2010
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesT Vilsbøll, J Rosenstock, H Yki-Järvinen, et al.
International Journal of Obesity (2005)|February 17, 2010
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose studyL J Aronne, S Tonstad, M Moreno, et al.
Obesity (Silver Spring, Md.)|April 10, 2010
A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie dietThomas A Wadden, Ken Fujioka, Soren Toubro, et al.
The Journal of Clinical Endocrinology and Metabolism|March 8, 2007
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adultsIra Gantz, Ngozi Erondu, Madhuja Mallick, et al.
Diabetes, Obesity & Metabolism|June 4, 2010
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetesM S Kipnes, P Hollander, K Fujioka, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
International Journal of Obesity (2005)|March 10, 2010
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose studyJ Proietto, A Rissanen, J B Harp, et al.
Obesity (Silver Spring, Md.)|April 12, 2007
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight lossNgozi Erondu, Thomas Wadden, Ira Gantz, et al.
Diabetes, Obesity & Metabolism|June 4, 2008
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyJ C N Chan, R Scott, J C Arjona Ferreira, et al.
Current Medical Research and Opinion|March 25, 2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialNir Barzilai, Hua Guo, Erin M Mahoney, et al.
International Journal of Clinical Practice|January 18, 2011
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetesK H Yoon, G R Shockey, R Teng, et al.
Diabetes, Obesity & Metabolism|January 23, 2010
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesT Vilsbøll, J Rosenstock, H Yki-Järvinen, et al.
International Journal of Obesity (2005)|February 17, 2010
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose studyL J Aronne, S Tonstad, M Moreno, et al.
Obesity (Silver Spring, Md.)|April 10, 2010
A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie dietThomas A Wadden, Ken Fujioka, Soren Toubro, et al.
The Journal of Clinical Endocrinology and Metabolism|March 8, 2007
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adultsIra Gantz, Ngozi Erondu, Madhuja Mallick, et al.
Diabetes, Obesity & Metabolism|June 4, 2010
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetesM S Kipnes, P Hollander, K Fujioka, et al.
Pageof 9